Astellas Pharma (4503.T) Earnings

In its last earnings report on April 23, 2025, Astellas Pharma reported earnings per share (EPS) of $41.84, compared to an estimated EPS of $26.11. The company reported revenue of $459.29B, compared to an estimated revenue of $453.90B.

Astellas Pharma's current Price-to-Earnings (P/E) ratio is 172.65. The trailing twelve months (TTM) P/E ratio is -45.00. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.

For the fiscal year ending March 31, 2024, Astellas Pharma reported total revenue of $1.60T and net income of $17.05B. This represents a net profit margin of 0.0106287321.

Astellas Pharma's earnings yield is 0.58%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.

Astellas Pharma's return on equity (ROE) is 1.07%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.

Astellas Pharma's gross profit margin is 81.76%. This indicates that for every dollar of revenue, the company retains $0.82 as gross profit after accounting for the cost of goods sold.